Signos is boosting its signal.
What’s happening: The CGM-enabled metabolic health platform raised $20M from GV (Google Ventures), BCBS Alabama, and Dexcom — with Signos now available to purchase on Dexcom’s DTC site.
Spiking. Built on Dexcom’s prescription-free Stelo device, Signos uses AI to interpret glucose response to food, movement, sleep, and stress, coaching users to avoid spikes.
Touting an FDA-cleared weight management program, demand from GLP-1 users has contributed to 10-fold growth over six months, with CEO Sharam Fouladgar-Mercer believing the category’s future will be defined by approaches merging “best of medication with the best of personalized data.”
Terms & conditions. For Dexcom, Signos’ tech expands the role of glucose biosensing beyond diabetes management. Delivering a “daily weight loss signal,” the joint system acts as a GLP-1 companion, enabling precision lifestyle adjustments over reliance on appetite suppression.
As Dexcom explores other metabolites like ketones and potassium, clinically backed Signos could become a copilot for managing chronic diseases.
Looking ahead: The first generation of consumer-facing CGMs decoded metabolic health. The next operationalizes glucose data as systems intelligence.
